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This examination consists of two sections. 
.
Section A consists of 100 rnultiple choice questions.
Section B consists of two(2) long questions,
Answer ALL question.
Answers to section A must be entered into the scripts provided.
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EegtLon A
Mark (/) the answers on the opposite space corresponding to a
correct or most appropriate answer for each question. Eachquestion has only one correct or most appropriate answer or
statement.
1. Which of the following statements is/are true?
(i) The administration of single daily doses ofgentamicin obviates the need to rnonitor its
plasma concentration.
(ii) Digoxin potentiates the nephrotoxicity ofgentamicin.
(iii) The dose of gentamicin should be reduced inpatients with nephrotic syndrome.
(iv) High perfonance liquid chromatography (HPLC)is the instrument of choice in the analysis
of plasna gentamicin concentration.
(a) All of the above statements are true.
(b) None of the above statements is true.
(c) only statements (i) and (ii) are true"
{d) only staternents (i) and (iii) are true.
2. Whj.ch of the following statements is true?
(a) The nethods cornmonly used to det,errnine serumdigoxin concentrations may be interfered with
by metabolites in patients with chronic renalfailure,
(b) The loading dose for digoxin, does not need to
be adjusted in patients with chronic renalfailure.
(c) Digoxin toxicity is potentiated by concurrent
hyperkalemia
(d) Digoxin elixir is less bioavailable thandigoxin tablet.
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3. Which of the following staternents is/are true?
i. An advantage of the TDx instrument is that it
can simultaneously run assays of nultiple drugsin the same sample
ii. The TDx instrument usually measures free drug
concentrations on1y.
iii. The shelf-Iife of a TDx reagent is usually about6 weeks.
iv. A disadvantage of a TDx instrument is that it is
non-specific.
(a) AIl of the above statements are true.
(b) None of the above statements is true"
(c) Only statements (i) and (ii) are true.
(d) Only statements (i) and (iii) are true,
4. Which of the following informatj.on is/are not essential in
interpreting plasma drug concentrations?
1. Age, weight, sex of the patient.
ii, Parameter estimates of the'drug monitored for thepatient.
iii. Parameter estimates of the drug monitored for thepopulation of sinilar patients.
iv. Clinical response of the patient..
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(a) A11 of the above inforrnation are not essential.
(b) None of the above information are is essential.
(c) Information contained in (ii) and (iii)
are not essential.
(d) fnformation contained in (ii), (iii) and (iv)
are not essential.
5. Which of the following statements is true about the
therapeutic drug monitoring of theophylline in the neonatalpatient?
(a) Plasma concentration obtained on the second
day after beginning theophylline tirerapy usually
represents a steady state.
(b) An over estimate of the pJ-asma concentration
nay be obtained from interference by theophy-lline metabolites.
(c) Two (2) g[rams of the intravenous formulation
contains more theophylline than 1 gram of
the oral formulation.
(d) None of the above statements is true.
5. Which of the following statements is/are not true about
the use and monitorinE of gentanicin?
i. In patlents with renal failure, the monitoring of
plasma concentration will avoid nephrotoxicity.
ii. Monitoring of input and output is useful to
monitor for the occurence of nephrotoxicity.
iii. The rise in serum creatinj-ne usually occur even
before any ehanges is seen in the elimj.nation
of gentamicin when the patlent develops nephro-
toxicity
iv. A peak of I ug/L is associated with nephro-
toxicity. 
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(a) AII of the above statements are true.
(b) None of the above statements is true.
(c) Only statements (ii) and (iii) are not true.
(d) Only statements (ii), (iii) and (iv) are nottrue.
7. Which of the following statements is true?
(a) A rapid bolus injection of gentamicin is
associated with an increased risk of toxicity.
(b) Phenytoin is not suitable for use in status
epilepticus.
(c) Absorption of carbamazepine is slovr and
erratic.
...,. (d) Plasma levels must be obtained for aII patientsgiven methotrexate
L Which of the following statements is true?
(a) Metabolism of theophylline is reduced inpatients with chronic renal failure.
(b) Chloranphenicol exhibits a useful post-
antibiotic effect.
(c) Aspirin exhibits a saturable elininationprocess,
(d) fntravenous chLoranphenicol usually gives a
nore reliable plasna chlorarnphenicol concentra-tions in pat,ients with typhoid.
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9. Which of the following statements is true?
(a) In-vitro i.nactivation occurs when gentamicin is
rnixed with erythromycin.
(b) The desired peak is higher for gentamicin thanit is for amikacin.
(c) Vancomycin can potentiate the ototoxicity of
amikacin.
(d) The therapeutic range for phenytoin is increasedin pat,ients with nephrotic syndrome,
10. Which of the following statements is true?
(a) Free plasrna phenytoin soncentration can only be
measured on the HPLC.
(b) It is not neccessary to vait six hours to obtaj.n
blood for plasma digoxin if the digoxin is gi-venparenterally
(c) Carbamazepine therapy should be started at a
lower dose in patients who are naive to carba-
mazepine.
(d) The dose of sodium valproate must be reduced inpatients with chronic renal failure.
11. Which of the following is not a barrier to compliance?
(a) Cost"
(b) Miscommunication.
(c) Unresolved concern.
(d) Mari.taI status.
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L2. which of the forlowing statements concerning noncom-pliance is not true ?
(a) Nonconplianee is sometimes inappropriately
viewed as abnornal patient behaviour.
(b) Noncompliance is overt when patients experiencebarriers to conpliance.
(c) Elderly maLes are more noncompliant than elderly
females.
(d) A personrs personality may be associated with
noncompJ.iance.
13. which of the following is/are conpliance program issuesfor the future?
(a) The value of compliance devices needs to be
verified.
(b) Future cornpliance technologj-es should linkpatient, physician and pharrnacist.
(c) Drug packaging, labeling, and inforrnation
can be developed to enhance patient conpliance.
(d) AlI of the above are correct.
L4. which of the forlortring is/are prerequisite(s) forpharrnacist to irnprove -conirtianle?
(a) fncentives for pharmacists cognitive services
must be included as part of the drug value,
(b) Patientsr unresolved concerns must beidentified and resolved.
(c) Industry support of the drug-use process through
education and compliance-promoting programs andproducts must be evident.
(d) A11 of the above are correct.
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15. Which of the following does not constitute a patient's drug-
taking problens?
(a) Modification of the dosage schedule.
(b) Self-medication with OTC drugs,
(c) Exacerbation of asthma.
(d) Inadequate knowledge on drugrs side-effects.
L6, Which of the following content of pharmacist cornmunica-
tions with the prescriber to clariflr a prescription is
considered unprof essional?
{a) Provide a clear, brief decription of thepotential problern.
(b) Cite a literature reference indicating the
clinical significance of the identified problen.
(c) Provj"des an alternative plan to solve theprescription problem.
(d) None of the above.
L7. Which of the following activities is nost important to
assist pharrnacists to improve counselling skills?
{a) Reading books on re}ated subject.
(b) Practising and obtai-ning feedback.
(c) Attending counselling workshops.
(d) None of the above.
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18. Which of the following is a long-term solution that can
be used to improve patient compl,iance?
(a) Pharmaceutical companies to develop product-
related compliance programs.
{b} Get pharmaceutical companies to sponsor
continuing education programs on compliance.
(c) CoJ.leges of pharrnacy should develop curriculum
to train graduates in counselling.
.,., o (d) None of the above is a long-term solutj-on.
19. Which of the f ollowing is part of pati.ent I s drug-taking
b6haviour leading to nonconpliance?
(a) Be1ief that the therapy will not work.
(b) Disagree with the diagnosis.
(c) Fear of side-effects.
(d) AIl of the above.
20" Which of the following issues related to patientrs
unresolved concerns about their disease and drug therapy is
false?
(a) Patients have questions about their diagnosis
and treatment. 
:(b) Patientsr perception of their own health does
not influence conpliance.
(c) The patientfs first opportunity to ask questionsis usually in the physicianrs office.
(d) Data from one study suggest that only one out
of e\tery four physicians diseusses a patient's
medications with the patient.
" :.'l
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2L. Which of the following would not be considered as a
compliance-promoting dosing formulation?
(a) Transdernal patch..
(b) Extended release.
(c) Once daily dosage.
(d) Depot injection.
22. Which of the following is/are advantage(s) of a pharrnacisttsparticipation in counselling activities?
(a) Identify patientrs drug-taking problems.
(b) Reduce the cost of outpatient drug therapy.
(c) (a) and {b) only
(d) None of the above.
23. Which of the following staternents regarding communication isfalse?
(a) A verbal communication sends a stronger messaqe
than a nonverbal eommunication.
(b) Pharrnacists must learn to be creative to
comrnunicate ef f ectively.
(c) Communicat,ion skills can be improved byparticipation in cornmunication workshop.
(d) ft is a dynarnic process between people.
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(a) Low socioeconomic status.
(b) Occurence of druErs side-effects.
(c) (a) and (b) only
(d) None of, the above.
actions wil.l
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physician for all
in the patientrs well
24. Which of the following is a rnajor contributor to
medication noncompl iance?
25. Which of the following pharmacists'
increase patient compiiince?
(a) Refering patient to thequestions.
(b) Appearance of interest
being.
(c) (a) and (b) on1y.
(d) None of the above.
26. which of the folrowing is/are a conseguence of partial com-pliance in a patient treated for chroriic nacterial infec-tion?'
(a) The need to perform additionaltests to evaluate renal function.
(b) The need to switch to a more complicated
regimen.
(c) Ttre need for a more toxic agent.
(d) All of the above.
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27. Which of the following variables
with patientrs cornpliance to drug
(FCP ss4)
signif icantly correlates
therapy?
(a) Age.
(b) Sex,
(c) Social status.
(d) Educational Ievel.
28. Which of the following contributes to
moment j-n a pharnacistrs counselling the optimal, teachablesession?
(a) . Conducted in a private consultation area.
(b) The unhurried pace of the pharmacist.
(c) Calling the patient by his/her name-
(d) All of the above
Zg. Which of the following reasons concerning the pharmacists
reluctance to participate in the counselLing activitiesis/are true?
The lack of ability
with the patients.
The Lack of tirne.
(a) and (b) only
None of the above.
to effectively communicate(a)
(b)
(c)
(d)
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30. The direct method of compliance measurement includes
(a) pilI counts.
(b) refill record.
(c) electronic rnonitoring device.
(d) nonitoring of serun drug concentration.
31. Which of the following methods of compliance assessment
may understimate true patient compliance?
(a) PiI1 counts,
(b) Measurement of therapeutj-c outcome.
(c) Patientrs self-report.
(d) Refill record,
32. Which of the following rnethods of conpliance assessmentis the most practicaL rneans of monitoring compliance in
clinical practice?
(a) Patientrs self-report.
(b) Medication history-taking.
(c) Electronic rnonitorj"ng device.
(d) Monitoring of serum drug concentration.
33" What is the main issue on patientrs noncompliance behavior?
(a) Inpact on the health-care cost.
(b) Impact on the health outcome
(c) fncrease in hospital re-admission.
(d) Increase in the incidence of drugrs adverse
effects.
...14/-
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34. Which of the following activities of the outpatientpharmacist is considered inappropriate?
{a) Detects and diagnoses adverse drug reactions anddrug interactions.
(b) Detects and overcomes incornpatibilities in drug
mixtures.
I (c) Performs drug utilization reviel,r and drug use
evaluations.
(d) None of the above.
35. The followings are examples of prescribing errors that
should be identified during prescription screening process,
except. .. .
(a) prescribe two drugs to obtain the benefit of
their additive effects.
{b) prescribe a drug for the unproved indication.
(c) prescribe a drug to treat another drugrs
side-effects.
(d) prescribe two drugs that act antagonistically at
the receptor site.
36. Which of the following is the rnost important reason forprefering a plasma drug }evel as a measurement forpatient compliance ?
(a) No other method of measuring compliance is
suff iciently accurate.
(b) The plasma level can easily be obtained at the
tine of the clinic appointrnent..
(c) To allow us to determine if the regimen j-s
therapeutic.
(d) The level cannot be faked by the patient.
...L5/-
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37 ' which of the following islare the reason for individualisedpatient counselling piocess?
(a) To expLore what the patients want to know.
e.... (b) To deternine what the patients need to know.
(c) To determine the scope of discussion withpatients.
(d) All of the above.
38. The pharmacists can have a positive inpact on clientsby.. ... .
(a) using written material to supplement counsellingactivities.
(b) serecting patients most in needs of complianceoriented counselling.
(c) notifying patients of their refills dates.
(d) a}l of the above.
' 39. A patient's perceptions about the desirability of healthcare delivery are shaped by all of the folloiling at,tiiudesexcept....
(a) cultural attitudes.
(b) religious attitudes.
(c) political attitudes.
(d) social at,titudes.
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40. During the initial patient,-practitioner encounter, which of
the following aspects of interaction contributes rnost to
increasing compliance?
.:... (a) Questioning the practitioner.
.. ... (b) Environmental considerations'
(c) Testing and trusting the practitioner.
(d) Economic arrangement"
41. A pharmacist who selectively retrieves drug information,
evlluate, interprete the literature and then provide an
answer to the question can be called .of drug
information,
(a) a retriever
(b) an informant
(p) an evaluator
(d) a consultant
42. Which of the following statements regardinE drug formularyis/are true?
(i) The only factor that should be considered for
drugs to be listed in the f,ormulary is its effec-
' tiveness and its pharmacokinetics.
(ii) It is a listing of pharmaceuticals and their
applications.
{iii} Its development should be guided by the objectivesto provide the best drug at any expense
(iv) The listings usually reflectF the current clinj-caljudgernent of the medical staffs.
474
,..L7 /-
L7 (FCP 5s4)
rNDEX NO:
(a) (i) and (iii) on1y.
(b) (ii) and (iv) onIy.
(c) (i), (ii) and (iii) only.
(d) (ii), (iii) and (iv) on1y.
43. when searching for infornation on drug, the reference thatthe pharmacist should consider first is..
(a) the general references.
..... (b) the primary references.
(c) Current Contents,
(d) Iowa Drug Information System (fDIS)
44. Which of the following are considered as tertiary reference?
(i) Drugdex.
(ii) Current Contents.
(iii) American Hospital Formulary Service - DrugInf ormat,ion.
(iv) Medline.
(a) (i) and (iii) on1y.
(b) (ii) and (iv) only,
(c) (i), (ii) and (iii) only.
(d) (ii), (iii) and (iv) on1y.
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45. Which of the following are objectives of c!|nical drug
monitoring?
(i) To maximise benefits.
(ii) To minimise risks.
(iii) To tailor therapy to individual patient.
(iv) To use the least expensive drug in all circum-
stances.
(a) (i) and (iii) onIY'
(b) (ii) and (iv) only.
(c) (i), (ii) and (iii) onIY.
. . . . . (d) (ii) , (iii) and (iv) only.
46. Adverse drug reactions due to allergic mechanism rarely
occur before of drug theraPY
(a) 1 week.
(b) 2 weeks.
(c) 3 weeks.
(d) 4 weeks.
47. Which of the following could be observed in adverse drug
reactions due to hypersensitivity reactions?
..... (a) Leucocytosis.
(b) Eosinophilia.
(c) Thrombocytopenia.
(d) Erythrocytosis.
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48. Which of the following step is not alvrays carried outin an atternpt to evaiuate the cause - effect relationshipof an adverse drug event?
(a) Identifying other etiologies,
(b) Determining chronologic sequence of event.
(c) Preview of patients previous medication history.
(d) Rechallenge the suspected drug.
49. During clinical drug monitoring, the pharrnacist need to knowthe therapeuti-c end point in order to..
(i) find faults with the doctorrs prescription.
(ii) determine the clinical significance of the
. 
problems identified.
(iii) conplete the patient,fs data.
(iv) assess the therapy.
(a) (i) and (iii) on1y.
(b) (ii) and (iv) on1y.
(c) (i), (ii) and (iii) only.
(d) (ii), (iii) and (iv) onJ.y.
50. Which of the following is not a method to initiate
correction of problems found from the Drug UtlizationEvaluation (DUE) activity?
(a) Educational programs.
(b) Linitations of prescribing.
(c) Formulary nodifications.
(d) WarninE letters.
.lr
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51. Which of the following staternents regarding DUE is true?
(a) DUE only involves the pharmacy department
staffs.
{b) The f,ina1 stage of a DUE is the initiation of
corrective actions.
(c) The evaluation can be disease or drugs orpatients specific.
(d) The criteria developed to measure quality should
only consists of objective criteria.
SZ. Which of the following background information is the least
irnportant when handling adverse drug rqaction questions?
(a) Patients drug historY.
(b) Indications for which the drug is beingprescribed.
(c) Suspected drug.
(d) The tirne course, dose and route of administra-
tion of suspected drug
53. Written response of drug infornation questions is done
(a) for all questions.
(b) when the answer is of suffici.ent value to keepfor future reference.
(c) when the pharmacists has the tine to write it"
(d) r.rhen the question is from a patient.
4?4
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54 ' which of the following references act,ually contain inforrna-tion from the pharrnac6uticar manufact,urers?
(i) Facts and Comparisons.
(ii) Drug fndex of Mataysia and Singapore (DrMS).
(iii) American. Hospitar Formulary service DrugInformat,ion (AHFS)
(iv) Physician Desk Reference (pDR).
(a) (i) and (iii) onJ.y.
(b) (ii) and (iv) ontry.
(c) (i), (ii) and (iii) onry.
(d) (ii), (iii) and (iv) onIy.
55. which of the forrowing references are best suited forpharmacists- to-.k9"p tract with the latest deveropment inpharmacy and medicine.
(i) Drugdex.
(ii) Current Contents Clinical practice.
(iii) Applied Therapeutics.
(iv) Inpharma.
(a) (i) and (iii) only
(b) (ii) and (iv) on1y.
(c) (i), (ii) and (iii) onty.
(d) (ii), (iii) and (iv) only.
475
...22/-
-22 (FcP 554)
INDEX NO:
56. Which of the following are causes of hypokaleniain a patidnt given parenteral nutrition?
(i) High fistulae output.
(ii) Fluid overload.
(ii-i) Post-acidosis st,ate after treatment with
sodium bicarbonate.
(iv) Polyuria.
(a) (i) and (ii) onIy.
(b) (i), (ii) and (iii) on1y.
(c) (i), (ii), (iii) and (iv).
(d) (ii) and (iv) only.
57. Which of the following steps are appropriate for the
management of catheter-related infection in a patient given
central parenteral nutrition?
(i) Irnmediate institution of empiric antibiotic
therapy.
(ii) Replacement of parenteral nutrition withdextrose 1Ot solution
(iii) Innediate withdrawal of the central
catheter.
(iv) Addition of heparin into parenteral
nutrition solution.
(a) (i) and (ii) only.
(b) (i), (ii) and (iii) on1y.
(c) {i), (ii), (iii) and (iv).
(d) (ii) and (iv) only.
47,6
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58. which of the folrowing is/are common source(s) of central
catheter related infections during infusion?
(i) Hands of nursing st,aff
(ii) Volumetric chambers containing extemporaneously
added drug.
(iii) Breath of the patient.
(iv) The use of a rrYrr connector to administer drug.
(a) (i) and (ii) only.
(b) (i), (ii) and (iii) on1y.
(c) (i), (ii), (iii) and (iv) .
(d) (ii) and (iv) onIy.
59. Which of the following statements
septicernia in a patieit receiving
(i) It occurs conmonly inpatient.
a f-a r-lq( (
are true regardingpare.nteral nutrition?
inmunocompromised
(ii) It is always associated with other fosi
of infection,
(iii) It occurs secondary to poor catheter care.
( iv) ft is alr.rays fatal.
(a) (i) and (ii) onIy.
(b) (i), (ii) and (iii) only.
(c) (ii, (ii), (iii) and (iv).
(d) (ii) and (iv) only.
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60. Which of the following complications are associated with
central line catheter?
(i) Air.embolism.
(ii) Hemothorax.
(iii) Thronbophi.ebitis,
( iv) Hernolysis.
(a) (i) and (ii) only.
(b) (i), (ii) and (iii) only.
(c) (i), (ii), (iii) and (iv).
(d) (ii) and (iv) only.
61. Which of the folloving statements are true regarding
hypergJ.ycemia in a patient receiving parenteral nutrition?
(i) It is associated with hypoinsulinemia.
(ii) It occurs as a result of rapid infusj-on
of hypertonic solution.
(iii) Heparin decreases the rate of elirnination
of glucose.
(iv) It is best managed initially by reducing the
rate of infusion
(a) (i) and (ii) onIy.
(b) (i), {ii) and (iii) onIy.
(c) (i), (ii), (iii) and (iv).
(d) (ii) and (iv) only.
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62. Which of the .following statements are true regardinghyperlipidernia in patients receiving parenteril nutiitionz
(i) It is associated with familial hyperlipidernia.
(ii) It is best avoided by adding heparininto the parenteral nutrition solution.
(iii) It is best, nanaged initially by reducingthe rate of infusion.
(iv) It results in atherosclerosis.
(a) (i) and (ii) on1y.
(b) (i), (ii) and (iii) only.
(c) (i), (ii), (iii) and (iv).
(d) (ii) and (iv) only.
63. Which of the following problens are associated with the use
of drugs in patients receiving parenteral nutrition?
(i)
( ii)
(iii)
( iv)
Interference with laboratory analysis.
Alteration of metaboiic profile.
Alteration of acid-base balance.
Precipitation of the parenteral nutrition
soluti.on.
(a) (i) and (ii) only.
(b) (i), (ii) and (iii) only.
(c) (i), (ii), (iii) and (iv)
(d) (ii) and (iv) oni.y.
. FI.alt / \l
'ltt,
...26/-
-26 (FCP 5s4)
INDEX NO:
64. Which of the f,ollowing stateuients regarding the management
of hyponatremia is true ?
(a)
(b)
(c)
(d)
Replacement should be given in patients witn
hypotonic hyponatremia.
Diuretic should be given in patients with'
hypotonic hyponatremia.
Fluid therapy should be instituted in patients
with hypotonic hYPernatremia.
Colloid should be given in patients with
hypotonic hyponatremia.
65. Which of the following staternents regarding hyperkalemia is
true ?
{a) Potassium level of 5 nEq/I in acidotic patients
requires inrnediate attention.
Hyperkalenia in alkalotic patients
requires immediate treatment.
Hyperkalemia in normal person indicates
excessive potassium intake.
Hyperkalemia in hernolysed samples indicate
water toxicitY.
66. Zinc deficiency may occur in the following condition.....
(a) high fistula outPut.
(b) post-burn case.
(c) severe diarrhea.
(d) prolonged infusion of zinc free totalparenteral nutrition.
(b)
(c)
(d)
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67 ' which of the following statements regarding the handling ofcytotoxic drugs is/are true ?
(i) Latex glove is safer than surgical glove.
(ii) Compliance to the right procedures is moreinportant than wearing protective garments.
(iii) Large powder spirlage should be cleaned usingspecial vacuum cleaner..
(iv) The formati-on of aerosol during the tranferincrprocesses can be avoided by maintaing positiv;pressure in the vial.
(a) i and ii on1y.
(b) i, ii and iii only.
(c) i, ii, iii and iv.
(d) iv only.
zt
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(c) Lung function tests.
(d) AII of the above.
68. which of the following baseline paraneters shourd bemonitored in arl pers6nnel worriirj i" i-.vt"I""i"laboratory?
{a) Blood pressure.
(b) Urinary rnutagen.
(rcP 554)
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69. Which of the following parameters should be monitored prior
to the initiation of total parenteral nutrition (TPN) ?
(i) Type and volume of fluid intake'
(ii) Serum biochernistry values.
(iii) Renal and liver function tests.
(iv) Nitrogen balance.
(a) i and ii on1y.
(b) i, ii and iii onlY.
(c) i, ii, iii and iv.
(d) iv on1y"
7A, Whj-ch of the following statements regardirrg hyperglycemia in
TPN patients is/are true ?
(i) It occurs as a result of hypoinsulinism.
(ii) It indicate the failure of pancreas to respond t,o
excessive glucose load.
(iii) It can be rnanaged by reducing the rate of
. infusion.
(iv) It is usually followed by hyponatremia.
(a) i and ii on1y.
(b) i, ii and iii onIY.
(c) i, ii, iii and iv.
(d) iv only.
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7L. Which of the following statements regarding effectivepharmacist-patient communication process is true ?
(a) Be sensitive to and keep to an acceptable
distance apart
(b) The quality of the communication depends more onduration than on interaction
(c) Non-verbal clues are almost insignificant during
prof essional conunication
. !... (d) Good communication is easy to provide in ahospital pharrnacy enviroment.
72. Which of the following questions is open-ended?
(a) rrYou are taking two of these tablet a day,
right?"
(b) rfHow many do you take each day?"
(c) trThis new medication hasnrt caused you
any problems, has it?tt
(d) ttDid the doctor tell you how to use
. the medication?tl
73. Which of the following questions is close-ended ?
(a) rr Did you take your rnedieine at home ?tl
(b) rr What do you think of this new nedication ?tl
.., r. (c) 'r It11 bet yourre feeling much betternarenrt you ?tl
(d) rr What, problems has the medication caused ?tl
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74, Which of the following statements regarding communication
technique is true ?
..... (a) Pharmacist should start using an open-endedquestion at the initial interview.
(b) use open-ended question to get more information
when communicating with a talkative patient.
{c) Use c}ose-ended question to get more' information when communicating with a quitepatient.
(d) Pharmacist should end an interview with
an open-ended question.
75. Which of the following techniques is useful to maximizepatientst understanding and memory during drug counselling?
(a) Speaking rapidly to provide all the necessary
informat,ion.
(b) Use of conplete sentences to elaborate facts
regardi.ng the drugs
. (c) l,tinirnising the number of facts given by providing
more general information.
..... (d) Providing a written back-up for the verbalinformation.
26. Which of the following corrective actions is not suitable to
overcome communication barriers arising from pharnacist ?
(a) Standing within 5 feet of patient"
(b) Controling distractions, such as nervous habits.
(c) Leaning toward Patient
td) Making eye contact at least 50-70 percent of thetirne.
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77. which of the forrowing cornbinations of communicati.onbarrier-corrective acfio" i; ;fi;";
(a) Distraction from lack of-privacy 
- maintaining
. 
appropriate interpersonal 
"pa""l(b) obstruction by fixed objects such as glasspartition 
- gn:uring no-inter$ii"; fromsupportive staff.
(c)'Exhibition-of inappropriate body movementadoption of open 6oay- postureo incro=sing ofarms and 1egs
(d) rnappropriate us€ ,of interpersonal spacestanding within 0.5 feet rlom pJ[i""t.
78' which of the forlowing statements regarding pharmacist-patient comrnunication process is true?
Communication is a one 
-rday process.
Communicatj_on demands effort, thought, time,and often times, noney.
The infornation and skills required forcommunication is the same ror'evEiv pili""t.
Communication must lce seen by patients topoint out their behaviour, ,i"L.i"-u"a Uuaeffect of noneompliance.
(a)
(b)
. . ... (c)
(d)
485
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79. Which
error
the following can be consi-dered a prescribing
Incorrect selection of drug, dose, dosageform, quantity for use of a dnlg product byillegible prescriPtion.
Administration of a rnedication not authorized
by a legitinate prescriber.
Administration of a drug product in adifferent dosage forrn that ordered by theprescriber.
Adninistration of rnedication outside apredefined tirne inteival from its scheduled
adrninistration time.
gO. Which of the followirrgs is classified as a dispensing error?
(a) Prescribing error.
(b) Monitoring error.
(c) Cornpliance error.
(d) omission error.
81. Which of the following personnel is not conmitted tohospital medication error?
of
?
(a)
{b)
{c)
(d)
(a)
(b)
(c)
(d)
Drug sale representatives.
Experienced physician.
Patients.
(a), (b) and (c) are aII committed to
medication error.
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82. Treatment with another drug or an increased rength ofstay is
(a) alevel0error.
(b) alevellerror.
(c) alevel2error.
..... (d) a level 4 error.
83. Which of the following nedication distribution systems hasthe highest incidence of nedication error?
(a) Floor stock + individual prescriptions.
(b) Individual prescriptions.
(c) Unit-dose distribution
(d) Floor stock + partial bulk supply of individualprescriptions.
84" Which of the following is an advantage of adecentralized unit doie distribution-system ?
(a) creater drug control and accountability.
(b) More communication within the ptrarmacy
departrnent.
(c) More space and equipnent is required.
(d) A more staffing flexibitity within thepharmacy department.
...34/-
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85, Which of the following is a disadvantage of a
centralized unit dose distribution system?
(a) More effective conmunication within the
department of PharmacY.
(b) More demand for drug infornation questions
. 
fron the doctor.
(c) Pharmacistrs clinical services are minimal and
not efficient.
(d) Current patient infoimatiorr is readily availablefor dispensing Pharrnacist '
86. Which of the following statements regarding decentralized
pharmacy serviee is true ?
(a) The two components of decentralized services
are drug inventory and dispensing.
(b) The drug distribution component is directed at'
rninirnizing nedication system error.
(c) It efficiency is determj.ned by the
irnplementation of a complete computerized
medication order.
(d) It is not cost-effective compared to a
centralized unit dose.
1Rl-
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87 , Which of the followingr staternents regardi-ng the role of costjustification in selllng clinical phirmacy programs is/are
- true?
(i) fnitially, clinical pharmacy was primarily
involved in the provision of druE-related
information.
(ii) Bootman and Zaske demonstrated reduced mortalityin burn patients with Gram-negative septicemia
after gentamicin pharmacokinetic monitoring
(iii) Most pharmacy organizations actively support the
concept of pharnaceutical care.
(iv) The development of pharnacy as a clinical
. profession has been we]I planned and directed
even from the beginning.
(a) If (i) and (ii) only is true.
..... (b) rf (i) and (iii) only is true.
(c) If (i), (ii) and (iii) only is true.
(d) If (iv) only is true.
88. Which of the following strategies are useful to make
pharmacy a truly clinical profession?
(a) Accepting the respo.nsibility for providing
pharmaceuti-cal care.
(b) Accepting the resposibility for the provision
of drug-related information"
(c) Accepting the responsibility for the provision
. of a unit dose distribution system.
(d) Accepting the responsibility for the provisi-on
of prescription screening in the outpatient
counter.
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89. Which of the following statements regarding the
establishnent of pharrnaceutical care is true?
(a) The most important part of the program
development is cost justification
(b) standards of practice are irnportant to ensure
success and resognition.
(c) The most important part of the program
development is the attitude of physician
toward Pharmacist'
(d) The most important' part of the program
development is the attitude of nurses toward
pharmacist.
90. Which of the following components differentiate ttre unit of
use distribution systin frbrn unit dose rnedication delivery
' systern?
..... (a) Patient Profile.
(b) Medication tro1leY.
(c) Amount of dose suPPlied.
(d) lrtedication order form.
91. Which of the following is considered a support service in
deLivering pharrnaceutical care?
(a) Unit dose distribution'
(b) Drug information service-
(c) Pharmacokinetic laboratory service'
(d) AII of the above.
490
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92. Which of the following is a major component of clj-nical drug
monitoring?
(a) Identification of actual or potential drug-
related problens
(b) Management of drug-related problems.
(c) Detection of drug i-nterastions.
(d) (a) and (b) .
93. Which of the following is the most important variable thatplaces a drug on the list of feasible alternatives?
(a) Efficacy and safety.
. . . .. (b) Cost of the alternatj.ve,
(c) Dosage practica}-ity.
(d) Drug-disease interaction.
94. Which of the following components is included in thepharmacistrs workup of drug therapy care plan?
(a) Any identified drug-related problem.
(b) Goals identified for nanaging those identified
problens
(c) A listing of therapeutic alternative andintervention made by the pharmacist to achieve
. the goa1s.
(d) (a), (b) and (c)
,at
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95, Which of the following causes patient to take
unnecessarY drug theraPY?
(a) Duplicated theraPY.
(b) Incorrect dose'
(c) Drug-drug interaction.
(d) Drug not available.
96. Which of the following causes the patient to take a
wrong druE?
(a) Drug-food interaction.
(b) Presence of a contraindication.
(c) Noncompliance
(d) Inability to swallow or administer the drug.
97. Which of the following causes the patient not to takehis/her drug?
(a) Drug-disease interaction.
(b) More effective therapy available'
(c) Inability to afford theraPY.
(d) Incorrect dose.
492
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98. Which of the following causes the patient to take too low adose of a drug?
(a) Untreated indication.
(b) Drug abuse.
(c) Unauthorized drug.
(d) Ihappropri.ate dosing intervaL.
99. Which of the foll"owing statements is true regarding the rate
of medication error in a unit dose medicati-on systen?
(a) It is higher than unit of use distribution
systern.
(b) ft is nainly due to.inexperienced personelsin dispensing.
(c) It does not justify the conversion of the wholedistribution system into this systen.
(d) It is lower than errors in the traditional
system.
l-oo. which of the following steps is the rnost difficult inquality assurance of distriUution services?
(a) Initiating unit dose.
(b) Acceptance of Pharmacy and Therapeutic Committe.
(c) Analysing data.
{d) Designing criteria or standard of quality.
'rq-{
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(5 narks)
Section B
I.
A. |Mr a 43 year old lady was diagnosed as having chronicintestinal obstruction since the rast 2 years. sne refused
orar feeding for the last 3 months and was maintained with2.5 liters of DE NS daiIy. The doctor requested thecrinical pharmaEistts opinion on the requirement for totalparenteral nutrition in this patient.
After reviewing the case, the crinical pharmacists agreed tostart TPN. This decision was made based on the patientrscurrent cli-nical and nutritional status.
(a) ff the patient's weight is 40 kg. and is 5 ft. 6 in.taIl, estimate SM daily energy requirements.
A 3-in-one TPN sorution was suggested to the d.octor. s daysaf,ter TPN was initiated, the patient developed cynosis
although the air entry was normal.
(b) Explain the possible reason for the cynosis in SM?
(4 marks)
(c) suggest appropriate steps to be taken to overcome sM
cynosis.
(3 narks)
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( 6 Marks )
B.
(a) What are the services provided by a good.drug
infornation center? Based on your experience,
discuss whether these services could be developed
in a drug information unit of the pharmacy
department in a general hosPital.
(b) You had just received a questj-on rr Can nitrofurantoin
cause leikocytosis and fever? rr Using watanabers
approach to handl-ing drug information question,
Oiicuss how you would tackle the above question'
2.
( 7 Marks ).
KyB is a 23 year old 40 kg. Ma1ay I?ay adrnitted to ward 85
tf nospitat ilSt'l for chronic rheumatic heart disease and
atrial- fibrillation. On admission, the patient was also
noted to have a nild renal impairement with blood'urea of
37.6 mmol/L and serum creatinine 256 mMoJ./L. Digoxin O'smg
stat was given to control the atrial fibril-lation' ft was
also planied that the patient be given digoxin O.25mg daily
orally for rnaintenance.
A. Comment on the dosage regimen of digoxin for KYB.
( 2.5 Marks )
B. Discuss the strategy for monitoring digoxin therapy
KYB.
( 10 Marks
496
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24 hours after the administration of the 0.5digoxin concentration was measured and foundnglnl.
ng
to
(rcP 5s4)
dose plasma
be 3.0
c. what is your assessment of the above d,igoxin concentration?
( 2.s Marks i
D. Discuss your plan of action for the above patient.
( 10 Marks )
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ApneJrdix
1. Ammonia 8O-1LO rncg/dt or 47-65 unol/L
2. Anilase 4-25 IU/nl
3 " BillirubinDirect o-0.2 mg/gL 0-3 umol/L
Indirect 0.2-0. e rng/dl 30-14 unoJ'/LTotatr A.z-t rng/dl 30-17 urnol/L
4. COz 20-30 mEq/L 24-30 nMoI/L
5. pCOZ 35-45 mnHg
5. cI LOO-106 mEq/L l-00-l-06 mMol/L
7. Cpk s0-170 ull,
8. Creatinine (SCr) 0.6-1.5 mg/dl 60-130 urnol/L
g.RandornbloodsugarT0-11omg/dI3-loumollL
L0. Iron 50-150 mca/dl 9'0-26'9 unol/L
11. Lactic 7A-2Lo lv/L
dehydrogenase
12. Magnessiurn t.5-2.0 rnEq/L 0'8-1-.3 nMollIJ
13. p,AZ 75-1OO mmHg
L4 . plr 7 .35-7 .45
15. Acid PhosPhataseMale o - 13-0. 63 IU/rnI 36'L7 6 nmol =-1i!-Fema1e0-101-0.65IU/rnI2.8-L56nrno]-s"/1"
L6.' A1kaline 39-117 IU/L
phosPhatase
LT.Phosphorous3.0-4.5n9/d1]-.0-1.5nMol/L
L8, Potassium {K+) 3.5-5. O rnEq/L 3.5-5.0 mMo}/L
l-9. Calcium (ca2+) 8. s-10. 5 ng/dl 2.L-2.6 nMol/L
20. Sodiurn (Na+1 135-145 mEq/L l-35-145 nMol/L
2L. Bicarbonate (HCO3-) 24-38 rnEq/L 24'28 nMoIlL
...44/'
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23.
24"
25.
26.
22. 'Protein
(scoT)
BUN
Uri,c Acid
27.
Total 6.0-8.5 g/dlAlbunin 3.5:5,0 g/dlGlobulin 2.3-3.5 g/dlTransferrin Z00-400 ng/dl
Transaminase 0-40 TV/L
44
8-25 mg/dl
3-7 n9/d1
45-522
37 
-48*
25-37 saat
105-150 rnl/nin/ L .7 3 n2
3 . o-7.5 mca/dl
25-3s*
t.3-4 .2
FCP 554)
60-85 g/L
35-50 glL
23-35 g/L
2.o-e . a glL
0-0.32 umol 
=-111,
2.9-8.9 mMol/L
0.18-0"42 mMolll,
Blood Pictr.lres
Red blood cell (RBC)Male 4.8-6.4 x ro9lrnmlFemale 4.2-5.4 x 1oo/mmrWhite blood cell(WBC) 4. O-t_l.0 x tO37rnrn3P 60-752L 20-40*,M 4_8tB 0_19E 1-3t
Platelate (plt) 200-4OO x tO37rnn3
ESR Male 0-10 mnljarn (Wintrobe)Female 0-15 rnrn/jarn (Wintrobe)
28, Hernatocrit
MaIe
Female
29. Hernoglobine (Hgb)
30.
3L.
32.
33.
34.
35.
Male 13-18 gldIFemale L2-L6 g/dl
Prothrombin tine 75-1OOt nilai asas(PT)
APTT
Creatinine
Clearance(crcl)
TTa
RT3U
FTI
'4'99
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NORM.TiL HEMODYNAMIC VALUES AND DERIVED TNDICES
SV
Normal Value Units
BP S/D/M Blood Pressure L2O/8A193 mm Hg
SYstol icl Diastol iclMean
co cardiac output 4-6 Liters/min.
RAP Right Atrial Pressure(l'tean) 2-6 mm Hg
pAP SID VI Pulmonary Artery.Pressure 25/t2/L6 mm Hg
SystoI ic/ Diastol iclMean
PCWP Pulrnonary Capillary Wedge s-LZ mm HgPressure (nean)
cr Cardiac Index 2'5-3'5 Liters/rninln2
CI=
BodY Surface Area
Stroke Volume 60 80 ml/beat
SV=
Heat Rate
SvI Stroke Volume Index 30 50 ml/beat/m2
svr
SVI=
Body Surface Area
PVR Pu1monarY Vascular
Resistance
MPAP - PCWP
PVR: x80
co
TPVR TotaL Peripheral Vascular 
-qResistance 90O-14O0 dynes'sec'cm "
MBP - RAPTPVR=# x 80
co
LVSWI Left Ventricular Stroke 
'Work Index 35-80 gm-m/m- lbeaE
LvSwI = (MBP-PCWP) (svl) (.0136)
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